NLS Pharmaceutics Aktie - NLSP

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

1,63

Gebot

1,58

Fragen

1,85

Volumen

0,00 Tagesbereich 0,00

1,47 52-Wochen-Bereich 18,388

Handelsende

1,63

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

3.076.378

Finanzvolumen

VWAP

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics CEO Issues Letter to Shareholders PR Newswire ZURICH, March 10, 2025 ZURICH, March 10, 2025...

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor...

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes...

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies PR...

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics PR Newswire ZURICH and NESS ZIONA, Israel...

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting PR Newswire ZURICH, Jan. 30, 2025 ZURICH...

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence PR Newswire ZURICH, Jan...

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS PR...

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Pri

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously...

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.03	1.875	1.6	1.775	1.5087	34420	1.62991755	CS
4	-0.68	-29.4372294372	2.31	2.36	1.47	124357	2.02923056	CS
12	-0.2	-10.9289617486	1.83	3.37	1.47	3076378	2.48893033	CS
26	-3.57	-68.6538461538	5.2	6.972	1.47	1592187	2.7425257	CS
52	-13.166	-88.9835090565	14.796	18.388	1.47	3963988	8.02942149	CS
156	-55.97	-97.1701388889	57.6	75.2	1.47	1480972	10.43310296	CS
260	-116.37	-98.6186440678	118	294	1.47	1707789	65.17960737	CS

NLSP - Frequently Asked Questions (FAQ)

What is the current NLS Pharmaceutics share price?

The current share price of NLS Pharmaceutics is US$ 1,63

What is the 1 year trading range for NLS Pharmaceutics share price?

NLS Pharmaceutics has traded in the range of US$ 1,47 to US$ 18,388 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
HCTIHealthcare Triangle Inc	US$ 0,5141 (58,18%)	4,04M
STISolidion Technology Inc	US$ 0,1748 (38,62%)	1,08M
PALIPalisade Bio Inc	US$ 1,26 (34,04%)	1,88M
SSPEW Scripps Company	US$ 1,89 (32,17%)	457,19k
LGCLLucas GC Ltd	US$ 0,7117 (31,00%)	1,65k
HEPAHepion Pharmaceuticals Inc	US$ 0,0518 (-38,33%)	1,36M
SKKSKK Holdings Limited	US$ 0,60 (-30,15%)	978
ZYXIZynex Inc	US$ 5,18 (-26,00%)	1,72k
TNONTenon Medical Inc	US$ 1,13 (-25,17%)	81,01k
STBXStarBox Group Holdings Ltd	US$ 0,2545 (-24,30%)	4,85k
HCTIHealthcare Triangle Inc	US$ 0,5141 (58,18%)	4,04M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8,28 (4,68%)	2,25M
PALIPalisade Bio Inc	US$ 1,25 (32,98%)	1,88M
SHViShares Short Treasury Bond ETF	US$ 110,235 (0,01%)	1,59M
HEPAHepion Pharmaceuticals Inc	US$ 0,0518 (-38,33%)	1,36M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NLS Pharmaceutics Ltd (NLSP)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

NLSP Neueste Nachrichten

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Pri

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLSP - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NLS Pharmaceutics Ltd (NLSP) Börsenkurse

NLS Pharmaceutics Ltd (NLSP)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

NLSP Neueste Nachrichten

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Pri

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLSP - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen